5000 A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines

M.Campone; N.Dobrovolskaya; S.Tjulandin; S.C.Chen; S.J.Fourié; F.Mefti; M.Konstantinova; J.C.Pouget; F.Lefresne; J.Jassem

首页> 外文期刊>European Journal of Cancer Supplements >5000 A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines

【24h】

5000 A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines

机译：5000一项三臂随机II期研究，对先前接受蒽环类药物治疗的转移性乳腺癌（MBC）患者口服长春瑞滨（NVBo）加卡培他滨（X）与NVBo和X进行比较，与序贯多西紫杉醇（D）和X进行比较

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
M.Campone; N.Dobrovolskaya; S.Tjulandin; S.C.Chen; S.J.Fourié; F.Mefti; M.Konstantinova; J.C.Pouget; F.Lefresne; J.Jassem;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines [J] . CamponeM., DobrovolskayaN., TjulandinS., The breast journal . 2013,第3期

机译：对先前接受蒽环类药物治疗的转移性乳腺癌患者进行口服长春瑞滨加卡培他滨对比口服长春瑞滨和卡培他滨对比多西他赛加卡培他滨的三臂随机II期研究
2. First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study [J] . A.Chan, V.Ganju, D.Becquart, European Journal of Cancer Supplements . 2008,第7期

机译：一线曲妥珠单抗（H），口服长春瑞滨（NVBo）和卡培他滨（X）联合治疗HER2阳性转移性乳腺癌（MBC）：一项跨国II期研究的有效性和安全性
3. First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study [J] . A.Chan, V.Ganju, D.Becquart, European Journal of Cancer Supplements . 2008,第7期

机译：一线曲妥珠单抗（H），口服长春瑞滨（NVBo）和卡培他滨（X）联合治疗HER2阳性转移性乳腺癌（MBC）：一项跨国II期研究的有效性和安全性
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01) [O] . In Hae Park, Seock-Ah Im, Kyung Hae Jung, 2019

机译：伊立替康联合卡培他滨与卡培他滨单药治疗以前用蒽环类和紫杉烷类治疗的转移性乳腺癌患者的随机开放标签III期试验：继续试验（KCSG BR 11-01）
6. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01) [O] . In Hae Park, Seock-Ah Im, Kyung Hae Jung, 2019

机译：Incotecan Plus Capecitabine的随机开放标签阶段III试验与先前用蒽环和紫杉烷治疗的转移性乳腺癌患者的Capecitabine单药治疗：进行试验（KCSG BR 11-01）

5000 A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines

著录项

相似文献

相关主题

期刊订阅